In vivo hepatic clearance of lipophilic drugs predicted by in vitro uptake data into cryopreserved hepatocytes suspended in sera of rats, guinea pigs, monkeys and humans

References

• Addison RS, Parker-Scott SL, Eadie MJ, et al. (2000). Steady-state dispositions of valproate and diflunisal alone and coadministered to healthy volunteers. Eur J Clin Pharmacol 56:715–21.
   PubMed Web of Science ®Google Scholar
• Baker M, Parton T. (2007). Kinetic determinants of hepatic clearance: plasma protein binding and hepatic uptake. Xenobiotica 37:1110–34.
   PubMed Web of Science ®Google Scholar
• Balani SK, Xu X, Pratha V, et al. (1997). Metabolic profiles of montelukast sodium (Singulair), a potent cysteinyl leukotriene1 receptor antagonist, in human plasma and bile. Drug Metab Dispos 25:1282–7.
   PubMed Web of Science ®Google Scholar
• Blanchard N, Hewitt NJ, Silber P, et al. (2006). Prediction of hepatic clearance using cryopreserved human hepatocytes: a comparison of serum and serum-free incubations. J Pharm Pharmacol 58:633–41.
   PubMed Web of Science ®Google Scholar
• Brunelle FM, Verbeeck RK. (1996). Glucuronidation of diflunisal in liver and kidney microsomes of rat and man. Xenobiotica 26:123–31.
   PubMed Web of Science ®Google Scholar
• Burczynski FJ, Wang GQ, Elmadhoun B, et al. (2001). Hepatocyte [3H]-palmitate uptake: effect of albumin surface charge modification. Can J Physiol Pharmacol 79:868–75.
   PubMed Web of Science ®Google Scholar
• Cappiello M, Giuliani L, Pacifici GM. (1991). Distribution of UDP-glucuronosyltransferase and its endogenous substrate uridine 5′-diphosphoglucuronic acid in human tissues. Eur J Clin Pharmacol 41:345–50.
   PubMed Web of Science ®Google Scholar
• Colussi D, Parisot C, Lefevre G. (1999). Binding of iralukast to serum proteins and erythrocytes: measurements using ultrafiltration and an erythrocyte partitioning method. Eur J Pharm Sci 7:167–73.
   PubMed Web of Science ®Google Scholar
• Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10:1093–5.
   PubMed Web of Science ®Google Scholar
• Howard ML, Hill JJ, Galluppi GR, McLean MA. (2010). Plasma protein binding in drug discovery and development. Comb Chem High Throughput Screen 13:170–87.
   PubMed Web of Science ®Google Scholar
• Ishiguro N, Maeda K, Kishimoto W, et al. (2006). Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans. Drug Metab Dispos 34:1109–15.
   PubMed Web of Science ®Google Scholar
• Iwatsubo T, Hirota N, Ooie T, et al. (1997). Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol Ther 73:147–71.
   PubMed Web of Science ®Google Scholar
• Izumi S, Nozaki Y, Kusuhara H, et al. (2018). Relative activity factor (RAF)-based scaling of uptake clearance mediated by organic anion transporting polypeptide (OATP) 1B1 and OATP1B3 in human hepatocytes. Mol Pharm 15:2277–88.
   PubMed Web of Science ®Google Scholar
• Kameyama Y, Yamashita K, Kobayashi K, et al. (2005). Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics 15:513–22.
   PubMed Web of Science ®Google Scholar
• Kopplow K, Letschert K, Konig J, et al. (2005). Human hepatobiliary transport of organic anions analyzed by quadruple-transfected cells. Mol Pharmacol 68:1031–8.
   PubMed Web of Science ®Google Scholar
• Lin JH, Hooke KF, Yeh KC, Duggan DE. (1985). Dose-dependent pharmacokinetics of diflunisal in rats: dual effects of protein binding and metabolism. J Pharmacol Exp Ther 235:402–6.
   PubMed Web of Science ®Google Scholar
• Mao J, Mohutsky MA, Harrelson JP, et al. (2012). Predictions of cytochrome P450-mediated drug–drug interactions using cryopreserved human hepatocytes: comparison of plasma and protein-free media incubation conditions. Drug Metab Dispos 40:706–16.
   PubMed Web of Science ®Google Scholar
• Matsushima S, Maeda K, Kondo C, et al. (2005). Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther 314:1059–67.
   PubMed Web of Science ®Google Scholar
• Miyauchi S, Masuda M, Kim SJ, et al. (2018). The phenomenon of albumin-mediated hepatic uptake of organic anion transport polypeptide substrates: prediction of the in vivo uptake clearance from the in vitro uptake by isolated hepatocytes using a facilitated-dissociation model. Drug Metab Dispos 46:259–67.
   PubMed Web of Science ®Google Scholar
• Muck W. (2000). Clinical pharmacokinetics of cerivastatin. Clin Pharmacokinet 39:99–116.
   Google Scholar
• Naritomi Y, Terashita S, Kimura S, et al. (2001). Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab Dispos 29:1316–24.
   PubMed Web of Science ®Google Scholar
• Noe J, Portmann R, Brun ME, Funk C. (2007). Substrate-dependent drug–drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab Dispos 35:1308–14.
   PubMed Web of Science ®Google Scholar
• Obach RS, Lombardo F, Waters NJ. (2008). Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug Metab Dispos 36:1385–405.
   PubMed Web of Science ®Google Scholar
• Shand DG, Cotham RH, Wilkinson GR. (1976). Perfusion-limited of plasma drug binding on hepatic drug extraction. Life Sci 19:125–30.
   PubMed Web of Science ®Google Scholar
• Tse FL, Jaffe JM, Troendle A. (1992). Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers. J Clin Pharmacol 32:630–8.
   Google Scholar
• Varma MV, Kimoto E, Scialis R, et al. (2017). Transporter-mediated hepatic uptake plays an important role in the pharmacokinetics and drug–drug interactions of montelukast. Clin Pharmacol Ther 101:406–15.
   PubMed Web of Science ®Google Scholar
• Varma MV, Steyn SJ, Allerton C, El-Kattan AF. (2015). Predicting clearance mechanism in drug discovery: extended clearance classification system (ECCS). Pharm Res 32:3785–802.
   PubMed Web of Science ®Google Scholar
• Watanabe T, Kusuhara H, Maeda K, et al. (2009a). Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther 328:652–62.
   PubMed Web of Science ®Google Scholar
• Watanabe T, Kusuhara H, Maeda K, et al. (2010). Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. Drug Metab Dispos 38:215–22.
   PubMed Web of Science ®Google Scholar
• Watanabe T, Kusuhara H, Watanabe T, et al. (2011). Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug–drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments. Drug Metab Dispos 39:1031–8.
   PubMed Web of Science ®Google Scholar
• Watanabe T, Maeda K, Kondo T, et al. (2009b). Prediction of the hepatic and renal clearance of transporter substrates in rats using in vitro uptake experiments. Drug Metab Dispos 37:1471–9.
   PubMed Web of Science ®Google Scholar
• Wilkinson GR, Shand DG. (1975). Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther 18:377–90.
   PubMed Web of Science ®Google Scholar